Home/Pipeline/Biosimilar/Biotech Programs

Biosimilar/Biotech Programs

Not Specified

ResearchActive

Key Facts

Indication
Not Specified
Phase
Research
Status
Active
Company

About Deva Holdings

Founded in 1958, Deva Holdings has grown from a domestic Turkish pharmaceutical player into an internationally recognized, publicly traded generics and API manufacturer. Its strategy is built on vertical integration, a strong R&D focus on bioequivalence, and geographic expansion into over 80 countries. Key achievements include establishing a significant export business, maintaining a diverse portfolio spanning multiple therapeutic areas, and operating a large-scale, end-to-end production infrastructure. The company's mission, 'For lives we add health to...', underscores its commercial focus on affordable, accessible medicine.

View full company profile

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved